Faron Pharmaceuticals Ltd. announced the appointment of Dr. Birge Berns, MD, as the Company's interim Chief Medical Officer (CMO). Dr. Berns will be based in the UK and her appointment is effective starting September 22, 2023. Dr. Berns succeeds Dr. Marie-Louise Fjällskog, who is stepping down from her current CMO role at Faron.

The Board of Directors have proposed to the Extraordinary General Meeting of the Company convened for tomorrow, September 22, 2023, that Dr. Fjällskog would be nominated to the Company's Board of Directors in a Non-Executive Director role. In this new role as a Non-Executive Director, Dr. Fjällskog would continue to play an integral role in the development of Faron's wholly owned immunotherapy asset, bexmarilimab, providing her clinical and regulatory expertise to support the Company's progress. Dr. Berns is a seasoned senior pharmaceuticals executive with a background in oncology, clinical medicine, rheumatology and immunology.

She brings more than 25 years' experience from senior leadership roles in global pharmaceutical companies, including Sanofi Aventis and Johnson & Johnson. Dr Berns is currently VP, Head of Clinical Development & Regulatory Strategy at tranScrip Limited, a strategic drug development partner that provides bespoke drug development services to pharma clients. She also serves as Chair of the Policy & Communication Group of the Faculty of Pharmaceutical Medicine, UK.